MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1.
10.19746/j.cnki.issn.1009-2137.2023.03.027
- Author:
Yue ZHANG
1
;
Ting-Ting CHEN
1
;
He-Bing ZHOU
2
,
3
;
Wen-Ming CHEN
4
Author Information
1. Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China.
2. Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China,E-mail: zhbyffs@
3. com.
4. Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Multiple Myeloma Research Center of Beijing, Beijing 100020, China,E-mail: xybxx@ccmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
JAG1;
cell cycle;
miR-203a-5p;
multiple myeloma;
proliferation
- MeSH:
Animals;
Mice;
Humans;
Multiple Myeloma/pathology*;
Cell Line, Tumor;
Mice, Nude;
MicroRNAs/metabolism*;
Cell Division;
Cell Proliferation;
Disease Models, Animal;
Carcinogenesis/genetics*;
Gene Expression Regulation, Neoplastic;
Jagged-1 Protein/metabolism*
- From:
Journal of Experimental Hematology
2023;31(3):801-809
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the biological function of miR-203a-5p and the underlying mechanism in multiple myeloma (MM).
METHODS:Three miRNA expression profiles (GSE16558, GSE24371 and GSE17498) were downloaded from the GEO database. The three miRNA expression profiles contained 131 MM samples and 17 normal plasmacyte samples. The robust rank aggregation (RRA) method was used to identify the differentially expressed miRNAs between MM and normal plasmacytes. In order to carry out cytological experiments, MM cell line with stable over-expression of miR-203a-5p was constructed with lentivirus. Expression levels of miR-203a-5p in MM cells were quantified by qRT-PCR. The effects of miR-203a-5p on MM cells were investigated using assays of cell viability and cell cycle. Cell proliferation was measured using the Cell Counting kit (CCK)8 assay. The percentage of cells in each cell cycle was measured with a FACSCalibur system. Xenograft tumor models were established to evaluate the role of miR-203a-5p in tumorigenesis in vivo . To elucidate the underlying molecular mechanisms of miR-203a-5p in mediating cell proliferation inhibition and cell cycle arrest in MM, we used TargetScan and miRanda to predict the candidate targets of miR-203a-5p. The potential target of miR-203a-5p in MM cells was explored using the luciferase reporter assay, qRT-PCR, and Western blot.
RESULTS:An integrated analysis of three MM miRNA expression datasets showed that the levels of miR-203a-5p in MM were notably downregulated compared with those in normal plasmacytes. Accordingly, the relative expression levels of miR-203a-5p were decreased in MM cell lines. In addition, overexpression of miR-203a-5p inhibited the proliferation and cell cycle progression of RPMI8226 and U266 cells. In vivo experiments demonstrated that upregulation of miR-203a-5p expression could significantly inhibit the tumorigenesis of subcutaneous myeloma xenografts in nude mice. Mechanistic investigation led to the identification of Jagged 1 (JAG1) as a novel and direct downstream target of miR-203a-5p. Interestingly, the reintroduction of JAG1 abrogated miR-203a-5p-induced MM cell growth inhibition and cell cycle arrest.
CONCLUSION:Our data demonstrate that miR-203a-5p inhibits cell proliferation and cell cycle progression in MM cells by targeting JAG1, supporting the utility of miR-203a-5p as a novel and potential therapeutic agent for miRNA-based MM therapy.
